File photograph: Vials labelled “VACCINE Coronavirus COVID-19” and a syringe are seen in entrance of displayed phrases “OMICRON SARS-COV-2” on this illustration taken December 11, 2021. REUTERS/Dado Ruvic/Illustration/File photograph Purchase Licensing Rights
Dec 5 (Reuters) – Novavax (NVAX.O) stated on Tuesday that Well being Canada had approved its up to date COVID-19 vaccine, concentrating on the Omicron subvariant XBB.1.5, in people aged 12 years and older.
Final month, WHO granted emergency-use authorization to the vaccine, which targets a descendant of the XBB lineage of the coronavirus that was globally predominant earlier this 12 months.
The U.S. Meals and Drug Administration and the European Fee approved using the up to date vaccine in October.
Novavax’s unique COVID shot acquired U.S. authorization in July 2022, lengthy after Pfizer and Moderna vaccines had been in use.
Reporting by Christy Santhosh; Enhancing by Shinjini Ganguli
Our Requirements: The Thomson Reuters Belief Ideas.
Discover more from PressNewsAgency
Subscribe to get the latest posts sent to your email.